These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
769 related articles for article (PubMed ID: 31097622)
1. Increased Lysosomal Exocytosis Induced by Lysosomal Ca Tsunemi T; Perez-Rosello T; Ishiguro Y; Yoroisaka A; Jeon S; Hamada K; Rammonhan M; Wong YC; Xie Z; Akamatsu W; Mazzulli JR; Surmeier DJ; Hattori N; Krainc D J Neurosci; 2019 Jul; 39(29):5760-5772. PubMed ID: 31097622 [TBL] [Abstract][Full Text] [Related]
2. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons. Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146 [TBL] [Abstract][Full Text] [Related]
3. Astrocytes Protect Human Dopaminergic Neurons from α-Synuclein Accumulation and Propagation. Tsunemi T; Ishiguro Y; Yoroisaka A; Valdez C; Miyamoto K; Ishikawa K; Saiki S; Akamatsu W; Hattori N; Krainc D J Neurosci; 2020 Nov; 40(45):8618-8628. PubMed ID: 33046546 [TBL] [Abstract][Full Text] [Related]
4. Identification of novel ATP13A2 interactors and their role in α-synuclein misfolding and toxicity. Usenovic M; Knight AL; Ray A; Wong V; Brown KR; Caldwell GA; Caldwell KA; Stagljar I; Krainc D Hum Mol Genet; 2012 Sep; 21(17):3785-94. PubMed ID: 22645275 [TBL] [Abstract][Full Text] [Related]
5. Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicity. Usenovic M; Tresse E; Mazzulli JR; Taylor JP; Krainc D J Neurosci; 2012 Mar; 32(12):4240-6. PubMed ID: 22442086 [TBL] [Abstract][Full Text] [Related]
6. Zn²⁺ dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation. Tsunemi T; Krainc D Hum Mol Genet; 2014 Jun; 23(11):2791-801. PubMed ID: 24334770 [TBL] [Abstract][Full Text] [Related]
7. α-Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson's disease occurs independent of ATP13A2 (PARK9). Daniel G; Musso A; Tsika E; Fiser A; Glauser L; Pletnikova O; Schneider BL; Moore DJ Neurobiol Dis; 2015 Jan; 73():229-43. PubMed ID: 25461191 [TBL] [Abstract][Full Text] [Related]
8. ATP13A2/PARK9 regulates secretion of exosomes and α-synuclein. Tsunemi T; Hamada K; Krainc D J Neurosci; 2014 Nov; 34(46):15281-7. PubMed ID: 25392495 [TBL] [Abstract][Full Text] [Related]
10. Lysosomal dysfunction in neurodegeneration: the role of ATP13A2/PARK9. Usenovic M; Krainc D Autophagy; 2012 Jun; 8(6):987-8. PubMed ID: 22561922 [TBL] [Abstract][Full Text] [Related]
11. Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Gitler AD; Chesi A; Geddie ML; Strathearn KE; Hamamichi S; Hill KJ; Caldwell KA; Caldwell GA; Cooper AA; Rochet JC; Lindquist S Nat Genet; 2009 Mar; 41(3):308-15. PubMed ID: 19182805 [TBL] [Abstract][Full Text] [Related]
13. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy. Cosden M; Jinn S; Yao L; Gretzula CA; Kandebo M; Toolan D; Hatcher NG; Ma L; Lemaire W; Adam GC; Burlein C; Minnick C; Flick R; Watt ML; Mulhearn J; Fraley M; Drolet RE; Marcus JN; Smith SM Neurobiol Dis; 2021 Nov; 159():105507. PubMed ID: 34509608 [TBL] [Abstract][Full Text] [Related]
14. ATP13A2 Regulates Cellular α-Synuclein Multimerization, Membrane Association, and Externalization. Si J; Van den Haute C; Lobbestael E; Martin S; van Veen S; Vangheluwe P; Baekelandt V Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33799982 [TBL] [Abstract][Full Text] [Related]
15. The Overcrowded Crossroads: Mitochondria, Alpha-Synuclein, and the Endo-Lysosomal System Interaction in Parkinson's Disease. Lin KJ; Lin KL; Chen SD; Liou CW; Chuang YC; Lin HY; Lin TK Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31731450 [TBL] [Abstract][Full Text] [Related]
17. Acid ceramidase inhibition ameliorates α-synuclein accumulation upon loss of GBA1 function. Kim MJ; Jeon S; Burbulla LF; Krainc D Hum Mol Genet; 2018 Jun; 27(11):1972-1988. PubMed ID: 29579237 [TBL] [Abstract][Full Text] [Related]
18. Hereditary Parkinsonism-Associated Genetic Variations in PARK9 Locus Lead to Functional Impairment of ATPase Type 13A2. Park JS; Sue CM Curr Protein Pept Sci; 2017; 18(7):725-732. PubMed ID: 26965689 [TBL] [Abstract][Full Text] [Related]
19. Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models. Prieto Huarcaya S; Drobny A; Marques ARA; Di Spiezio A; Dobert JP; Balta D; Werner C; Rizo T; Gallwitz L; Bub S; Stojkovska I; Belur NR; Fogh J; Mazzulli JR; Xiang W; Fulzele A; Dejung M; Sauer M; Winner B; Rose-John S; Arnold P; Saftig P; Zunke F Autophagy; 2022 May; 18(5):1127-1151. PubMed ID: 35287553 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration. Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]